DOI QR코드

DOI QR Code

Presence of Sarcopenia and Its Rate of Change Are Independently Associated with Long-term Mortality in Patients with Liver Cirrhosis

  • Jeong, Jae Yoon (Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine) ;
  • Lim, Sanghyeok (Department of Radiology, Hanyang University Guri Hospital, Hanyang University College of Medicine) ;
  • Sohn, Joo Hyun (Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine) ;
  • Lee, Jae Gon (Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine) ;
  • Jun, Dae Won (Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine) ;
  • Kim, Yongsoo (Department of Radiology, Hanyang University Guri Hospital, Hanyang University College of Medicine)
  • Received : 2018.03.09
  • Accepted : 2018.09.13
  • Published : 2018.12.10

Abstract

Background: Sarcopenia is associated with a poor prognosis in patients with liver cirrhosis. However, it is not known whether the rate of skeletal muscle depletion is also associated with a poor prognosis. We investigated the prognostic impact of the rate of skeletal muscle depletion in patients with liver cirrhosis. Methods: We included retrospectively all patients with liver cirrhosis who underwent both multiple computed tomography scans and hepatic venous pressure gradient (HVPG) measurements. Results: A total of 131 patients with liver cirrhosis were enrolled. The mean age of the patients was 53.7 years and alcoholic liver disease was the most common cause (61.8%). Sixty-four patients (48.9%) were diagnosed with sarcopenia. The median changes in skeletal muscle area per year (${\Delta}SMA/y$) were -0.89%. During a median follow-up period of 46.2 months (range, 3.4-87.6), 45 patients (34.4%) died. In multivariate analyses, age, Child-Pugh score, HVPG, presence of sarcopenia and ${\Delta}SMA/y$ were independently associated with mortality. Cumulative mortality was significantly higher in patients with ${\Delta}SMA/y$ < -2.4% than those with ${\Delta}SMA/y{\geq}-2.4%$ (log-rank test, P < 0.001). Conclusion: Both the presence and rate of change of sarcopenia are independently associated with long-term mortality in patients with liver cirrhosis.

Keywords

References

  1. Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr 2017;36(1):49-64. https://doi.org/10.1016/j.clnu.2016.09.004
  2. Santilli V, Bernetti A, Mangone M, Paoloni M. Clinical definition of sarcopenia. Clin Cases Miner Bone Metab 2014;11(3):177-80.
  3. Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer 2016;57:58-67. https://doi.org/10.1016/j.ejca.2015.12.030
  4. van Vugt JL, Levolger S, de Bruin RW, van Rosmalen J, Metselaar HJ, IJzermans JN. Systematic review and meta-analysis of the impact of computed tomography-assessed skeletal muscle mass on outcome in patients awaiting or undergoing liver transplantation. Am J Transplant 2016;16(8):2277-92. https://doi.org/10.1111/ajt.13732
  5. Anker SD, Morley JE, von Haehling S. Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle 2016;7(5):512-4. https://doi.org/10.1002/jcsm.12147
  6. Durand F, Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis 2008;28(1):110-22. https://doi.org/10.1055/s-2008-1040325
  7. Kim TY, Kim MY, Sohn JH, Kim SM, Ryu JA, Lim S, et al. Sarcopenia as a useful predictor for long-term mortality in cirrhotic patients with ascites. J Korean Med Sci 2014;29(9):1253-9. https://doi.org/10.3346/jkms.2014.29.9.1253
  8. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60(8):646-9. https://doi.org/10.1002/bjs.1800600817
  9. Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004;40(6):897-903. https://doi.org/10.1016/j.jhep.2004.02.010
  10. Ripoll C, Banares R, Rincon D, Catalina MV, Lo Iacono O, Salcedo M, et al. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. Hepatology 2005;42(4):793-801. https://doi.org/10.1002/hep.20871
  11. Kim HJ, Lee HW. Important predictor of mortality in patients with end-stage liver disease. Clin Mol Hepatol 2013;19(2):105-15. https://doi.org/10.3350/cmh.2013.19.2.105
  12. Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007;133(2):481-8. https://doi.org/10.1053/j.gastro.2007.05.024
  13. Kim TY, Lee JG, Sohn JH, Kim JY, Kim SM, Kim J, et al. Hepatic venous pressure gradient predicts long-term mortality in patients with decompensated cirrhosis. Yonsei Med J 2016;57(1):138-45. https://doi.org/10.3349/ymj.2016.57.1.138
  14. Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol 2016;65(6):1232-44. https://doi.org/10.1016/j.jhep.2016.07.040
  15. Sinclair M, Gow PJ, Grossmann M, Angus PW. Review article: sarcopenia in cirrhosis--aetiology, implications and potential therapeutic interventions. Aliment Pharmacol Ther 2016;43(7):765-77. https://doi.org/10.1111/apt.13549
  16. Montano-Loza AJ, Meza-Junco J, Prado CM, Lieffers JR, Baracos VE, Bain VG, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012;10(2):166-73. https://doi.org/10.1016/j.cgh.2011.08.028
  17. DiMartini A, Cruz RJ Jr, Dew MA, Myaskovsky L, Goodpaster B, Fox K, et al. Muscle mass predicts outcomes following liver transplantation. Liver Transpl 2013;19(11):1172-80. https://doi.org/10.1002/lt.23724
  18. Montano-Loza AJ, Duarte-Rojo A, Meza-Junco J, Baracos VE, Sawyer MB, Pang JX, et al. Inclusion of sarcopenia within MELD (MELD-Sarcopenia) and the prediction of mortality in patients with cirrhosis. Clin Transl Gastroenterol 2015;6(7):e102. https://doi.org/10.1038/ctg.2015.31
  19. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985) 2004;97(6):2333-8. https://doi.org/10.1152/japplphysiol.00744.2004
  20. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol (1985) 1998;85(1):115-22. https://doi.org/10.1152/jappl.1998.85.1.115
  21. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008;9(7):629-35. https://doi.org/10.1016/S1470-2045(08)70153-0
  22. Hanai T, Shiraki M, Ohnishi S, Miyazaki T, Ideta T, Kochi T, et al. Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis. Hepatol Res 2016;46(8):743-51. https://doi.org/10.1111/hepr.12616
  23. Montano-Loza AJ. Clinical relevance of sarcopenia in patients with cirrhosis. World J Gastroenterol 2014;20(25):8061-71. https://doi.org/10.3748/wjg.v20.i25.8061
  24. Grimby G, Saltin B. The ageing muscle. Clin Physiol 1983;3(3):209-18. https://doi.org/10.1111/j.1475-097X.1983.tb00704.x
  25. Jang HC. Sarcopenia, frailty, and diabetes in older adults. Diabetes Metab J 2016;40(3):182-9. https://doi.org/10.4093/dmj.2016.40.3.182
  26. Hanai T, Shiraki M, Nishimura K, Ohnishi S, Imai K, Suetsugu A, et al. Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition 2015;31(1):193-9. https://doi.org/10.1016/j.nut.2014.07.005
  27. Tsien C, Shah SN, McCullough AJ, Dasarathy S. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol 2013;25(1):85-93. https://doi.org/10.1097/MEG.0b013e328359a759
  28. Plauth M, Cabre E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J, et al. ESPEN Guidelines on Enteral Nutrition: liver disease. Clin Nutr 2006;25(2):285-94. https://doi.org/10.1016/j.clnu.2006.01.018
  29. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014;60(2):715-35. https://doi.org/10.1002/hep.27210
  30. Gluud LL, Dam G, Les I, Marchesini G, Borre M, Aagaard NK, et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev 2017;5:CD001939.
  31. Tsien C, Davuluri G, Singh D, Allawy A, Ten Have GA, Thapaliya S, et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. Hepatology 2015;61(6):2018-29. https://doi.org/10.1002/hep.27717
  32. Matsumura T, Morinaga Y, Fujitani S, Takehana K, Nishitani S, Sonaka I. Oral administration of branched-chain amino acids activates the mTOR signal in cirrhotic rat liver. Hepatol Res 2005;33(1):27-32. https://doi.org/10.1016/j.hepres.2005.07.001
  33. Kawaguchi T, Shiraishi K, Ito T, Suzuki K, Koreeda C, Ohtake T, et al. Branched-chain amino acids prevent hepatocarcinogenesis and prolong survival of patients with cirrhosis. Clin Gastroenterol Hepatol 2014;12(6):1012-8.e1. https://doi.org/10.1016/j.cgh.2013.08.050
  34. Park JG, Tak WY, Park SY, Kweon YO, Jang SY, Lee YR, et al. Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease: a Korean nationwide, multicenter, retrospective, observational, cohort study. Medicine (Baltimore) 2017;96(24):e6580. https://doi.org/10.1097/MD.0000000000006580
  35. Sinclair M, Grossmann M, Hoermann R, Angus PW, Gow PJ. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: a randomised controlled trial. J Hepatol 2016;65(5):906-13. https://doi.org/10.1016/j.jhep.2016.06.007
  36. Moller S, Becker U, Gronbaek M, Juul A, Winkler K, Skakkebaek NE. Short-term effect of recombinant human growth hormone in patients with alcoholic cirrhosis. J Hepatol 1994;21(5):710-7. https://doi.org/10.1016/S0168-8278(94)80228-9
  37. Fagundes C, Barreto R, Guevara M, Garcia E, Sola E, Rodriguez E, et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol 2013;59(3):474-81. https://doi.org/10.1016/j.jhep.2013.04.036
  38. Piano S, Rosi S, Maresio G, Fasolato S, Cavallin M, Romano A, et al. Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol 2013;59(3):482-9. https://doi.org/10.1016/j.jhep.2013.03.039
  39. Montano-Loza AJ, Meza-Junco J, Baracos VE, Prado CM, Ma M, Meeberg G, et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. Liver Transpl 2014;20(6):640-8. https://doi.org/10.1002/lt.23863
  40. Dahya V, Xiao J, Prado CM, Burroughs P, McGee D, Silva AC, et al. Computed tomography-derived skeletal muscle index: a novel predictor of frailty and hospital length of stay after transcatheter aortic valve replacement. Am Heart J 2016;182:21-7. https://doi.org/10.1016/j.ahj.2016.08.016

Cited by

  1. The Impact of Sarcopenia and Its Rate of Change on Prognostic Value of Liver Cirrhosis vol.33, pp.50, 2018, https://doi.org/10.3346/jkms.2018.33.e334
  2. A Comprehensive Review of Outcome Predictors in Low MELD Patients vol.104, pp.2, 2018, https://doi.org/10.1097/tp.0000000000002956
  3. A Low Geriatric Nutritional Risk Index is Associated with Aggressive Pathologic Characteristics and Poor Survival after Nephrectomy in Clear Renal Cell Carcinoma: A Multicenter Retrospective Study vol.72, pp.1, 2020, https://doi.org/10.1080/01635581.2019.1621357
  4. Sarcopenia in chronic liver diseases: a translational overview vol.14, pp.5, 2020, https://doi.org/10.1080/17474124.2020.1757427
  5. Nutrition in alcohol-related liver disease: Physiopathology and management vol.26, pp.22, 2018, https://doi.org/10.3748/wjg.v26.i22.2916
  6. Computed Tomography-Determined Body Composition Abnormalities Usefully Predict Long-term Mortality in Patients With Liver Cirrhosis vol.45, pp.5, 2018, https://doi.org/10.1097/rct.0000000000001207